Genomic Health, Inc. (NASDAQ:GHDX) has received an average recommendation of “Hold” from the eleven research firms that are currently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $32.67.
GHDX has been the subject of several research analyst reports. Zacks Investment Research downgraded Genomic Health from a “hold” rating to a “strong sell” rating in a report on Friday, March 9th. JPMorgan Chase & Co. downgraded Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 price objective for the company. in a report on Wednesday, December 13th. Barclays reissued a “sell” rating and issued a $28.00 price objective on shares of Genomic Health in a report on Monday, January 8th. Canaccord Genuity reissued a “buy” rating and issued a $39.00 price objective on shares of Genomic Health in a report on Wednesday, November 15th. Finally, ValuEngine raised Genomic Health from a “sell” rating to a “hold” rating in a report on Friday, December 15th.
In related news, COO G Bradley Cole sold 5,000 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $35.51, for a total transaction of $177,550.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider James J. Vaughn sold 3,004 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $34.09, for a total value of $102,406.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 84,280 shares of company stock valued at $2,812,296. Corporate insiders own 46.20% of the company’s stock.
Genomic Health (GHDX) opened at $32.42 on Wednesday. The company has a market cap of $1,130.00, a P/E ratio of -294.73 and a beta of 0.61. Genomic Health has a one year low of $26.54 and a one year high of $37.50.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Thursday, March 8th. The medical research company reported $0.08 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.09 by ($0.01). The firm had revenue of $87.50 million during the quarter, compared to analyst estimates of $88.96 million. Genomic Health had a negative net margin of 1.13% and a negative return on equity of 0.85%. Genomic Health’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.04 earnings per share. analysts expect that Genomic Health will post 0.39 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Genomic Health, Inc. (GHDX) Given Average Rating of “Hold” by Brokerages” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://sportsperspectives.com/2018/03/14/genomic-health-inc-ghdx-given-average-rating-of-hold-by-brokerages-2.html.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.